TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34226654
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH, Genotonorm 0.4 mg, Pfizer Pharmaceuticals) administered subcutaneously daily for one year
Study: 34226654
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously daily for one year
Study: 35222690
Drug: 3D-slicer software-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3D-slicer software-assisted endoscopic treatment
Study: 32618242
Drug: Focal Mass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal Mass Drug Administration (fMDA)
Study: 32424833
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment and Hall crown approaches (ARTs)
Study: 36975369
Drug: V160 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: V160 vaccine
Study: 35599912
Drug: Pre-sleep protein
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-sleep protein (PRO) supplement containing 40 g of casein protein (n=10)
Study: 32441675
Drug: Nurse-provided education
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-provided education about chemotherapy-associated taste disorders
Study: 35251294
Drug: Anlotinib in
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib in combination with other drugs
Study: 35251294
Drug: Anlotinib monotherapy
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib monotherapy
Study: 35869707
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical treatment
Study: 35901983
Drug: Placebo delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivery (0 mg)
Study: 35901983
Drug: Steady-state delivery
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steady-state delivery (2 mg)
Study: 35901983
Drug: Random nicotine
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random nicotine delivery (RND) (0 mg or 4 mg)
Study: 32211998
Drug: Control (motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (motor control training and manual therapy)
Study: 34157312
Drug: 5 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg/d Cu-IUS
Study: 34157312
Drug: 20 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg/d Cu-IUS
Study: 34157312
Drug: 40 µg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 µg/d Cu-IUS
Study: 35278356
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by chemotherapy plus durvalumab and tremelimumab
Study: 35278356
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus durvalumab
Study: 35278356
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus durvalumab and tremelimumab
Study: 36321352
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under fasting conditions
Study: 36321352
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (KCl) sustained-release tablets, oral dose of 6 g under different dietary arrangements
Study: 32383050
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg per day)
Study: 32383050
Drug: Gabapentin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (100 mg per day)
Study: 34858310
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of training and tDCS
Study: 34867115
Drug: Intelligent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intelligent training system, twice a day, 20 minutes each time.
Study: 35857752
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) 2 g daily
Study: 33899191
Drug: 3g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of magnesium sulfate in 100mL of glucose solution (Group A)
Study: 33899191
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of glucose solution (Group B)
Study: 35551291
Drug: PGDM1400, PGT121,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGDM1400, PGT121, and VRC07-523LS (20 mg kg−1 each)
Study: 35751528
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d.
Study: 35751528
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg o.d.
Study: 33029705
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (2 mg/kg up to 50 mg per day)
Study: 35868342
Drug: Pay-it-forward intervention
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pay-it-forward intervention (free influenza vaccine and opportunity to donate)
Study: 32933577
Drug: Ordinary PAP
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary PAP treatment at the health care centre (HCC group)
Study: 35576638
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg magnolol (M300)
Study: 35576638
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg honokiol (H300)
Study: 35576638
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg total phenols with a magnolol/honokiol ratio of 2:1 (M200H100)
Study: 35576638
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg total phenols with a magnolol/honokiol ratio of 1:2 (M100H200)
Study: 35576638
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg total phenols with a magnolol/honokiol ratio of 1:1 (M150H150)
Study: 34704866
Drug: MindfulGarden (MG),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MindfulGarden (MG), a digital calming device, used during morning and evening care for 3 days, followed by exposure with verbal prompting on Day 4.
Study: 35845514
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg esketamine, i.v.
Study: 35845514
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg esketamine, i.v.
Study: 34126044
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy at a dose of 24 Gy in two daily fractions
Study: 34126044
Drug: Conventional external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional external beam radiotherapy at a dose of 20 Gy in five daily fractions
Study: 37133765
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy‐Bladder Cancer (FACT‐BL)
Study: 33620008
Drug: Topical LAA
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical LAA solution
Study: 33710166
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy for 12 weeks
Study: 35835612
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IP)
Study: 32839221
Drug: RO7049389 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 (single dose of 150 to 2,500 mg)
Study: 32839221
Drug: RO7049389 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 (multiple doses of 200 to 800 mg)
Study: 32839221
Drug: RO7049389 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 (450 mg) under fasted and fed conditions
Study: 32839221
Drug: RO7049389 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7049389 (up to a single dose of 2,500 mg)
Study: 34648192
Drug: Fluconazole (CYP2C19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (CYP2C19 inhibitor)
Study: 34648192
Drug: Ciprofloxacin (CYP1A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (CYP1A2 inhibitor)
Study: 34648192
Drug: Ciprofloxacin/Fluconazole (combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin/Fluconazole (combination)
Study: 32753063
Drug: Paracetamol-diclofenac (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-diclofenac (1g + 75mg)
Study: 32753063
Drug: Paracetamol-tramadol (1g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol-tramadol (1g + 100mg)
Study: 36858151
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg/day) plus ADT
Study: 33400012
Drug: High-Intensity Laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Laser Therapy (HILT) + exercise
Study: 35965421
Drug: Propolis (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (300 mg)
Study: 33326371
Drug: Prenatal vitamin
Normalized name: Prenatal Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal vitamin D supplementation (2 oral doses of 50,000 IU)
Study: 33581259
Drug: Palonosetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (all doses)
Study: 32265083
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.7 μg/kg/h in the operating room and 0.4 μg/kg/h in the ICU)
Study: 35469330
Drug: Dexmedetomidine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine administration
Study: 35994795
Drug: Aromatherapy through
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy through the skin and by inhalation
Study: 34304467
Drug: Intratympanic injection
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic injection of methylprednisolone (control group)
Study: 32629078
Drug: Dose-escalated arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-escalated arm (up to 95 Gy prescribed to the tumor)
Study: 32629078
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (dose constraints to organs at risk)
Study: 36125170
Drug: Advertisement for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advertisement for a hypothetical cold sore medicine
Study: 34537448
Drug: Bronchoscopic airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoscopic airway clearance therapy (B-ACT)
Study: 34521593
Drug: 1,25-hydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-hydroxyvitamin D3 plus amoxicillin, clarithromycin, and esomeprazole for 2 weeks
Study: 34521593
Drug: Standard clarithromycin-based
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard clarithromycin-based triple therapy (amoxicillin, clarithromycin, and esomeprazole for 2 weeks)
Study: 35129534
Drug: 4-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day antibiotic duration (experimental arm of STOP-IT RCT)
Study: 35129534
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic duration (control group)
Study: 36163806
Drug: Ivosidenib (IVO)
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivosidenib (IVO) 500 mg once daily plus Azacitidine (AZA) 75 mg/m2 for 7 days in 28-day cycles
Study: 36163806
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) plus Azacitidine (AZA) 75 mg/m2 for 7 days in 28-day cycles
Study: 34628889
Drug: ATD (methimazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATD (methimazole, 15-30 mg/day)
Study: 36055467
Drug: H‐1337 Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐1337 Ophthalmic Solution 0.06%
Study: 36055467
Drug: H‐1337 Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐1337 Ophthalmic Solution 0.20%
Study: 36055467
Drug: H‐1337 Ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐1337 Ophthalmic Solution 0.60%
Study: 36055467
Drug: H‐1337 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐1337 (all doses combined)
Study: 33773189
Drug: Carvacrol (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvacrol (1.2 mg/kg/day, n = 17)
Study: 34505292
Drug: 3-month psychological
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month psychological intervention in addition to standard physiological treatment
Study: 34505292
Drug: Standard physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physiological treatment
Study: 35552364
Drug: Etirinotecan pegol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol, 145 mg/m2, every 21 days
Study: 35552364
Drug: Chemotherapy (eribulin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel)
Study: 37465907
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2400 mg/day
Study: 35418247
Drug: Values-affirmation intervention
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Values-affirmation intervention on medication adherence
Study: 33704444
Drug: ART (Antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART (Antiretroviral Therapy)
Study: 33176757
Drug: Hyperthermic baths
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperthermic baths (HTB) twice weekly for 8 weeks (n = 22)
Study: 33176757
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise program (PEP) of moderate intensity twice weekly for 8 weeks (n = 23)
Study: 35237338
Drug: Needle-warming moxibustion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-warming moxibustion combined with hyperbaric oxygen therapy (NWM + HBOT)
Study: 35863947
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL bolus every 45 min
Study: 35863947
Drug: 6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL bolus every 45 min
Study: 35863947
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL bolus every 45 min
Study: 34238445
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg plus Ezetimibe 10 mg (ATO10/EZE10)
Study: 34238445
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg alone (ATO40)
Study: 35566482
Drug: Intravenous Ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Ferric Carboxymaltose (FCM)
Study: 37257948
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care with rapid uptitration of oral medications for heart failure
Study: 36067063
Drug: Daratumumab subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab subcutaneous (DARA SC)
Study: 36067063
Drug: Daratumumab intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab intravenous (DARA IV)
Study: 33083852
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges (Lactobacillus brevis CD2)
Study: 33514427
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose umbilical cord MSCs (200 × 10^6 cells, 3 infusions every other day for a total of 600 × 10^6 cells)
Study: 33514427
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose placental MSCs (200 × 10^6 cells, 3 infusions every other day for a total of 600 × 10^6 cells)
Study: 33514427
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MSCs (both UC-MSCs and PL-MSCs)
Study: 39114916
Drug: Glucose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (30 g)
Study: 33507929
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg buccal 40% dextrose gel
Study: 35954979
Drug: Exercise toolkit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise toolkit intervention (stick, theraband, sandbag, small ball) led by a physical therapist, 90 min per session, twice weekly for 3 months
Study: 34803399
Drug: Transversus thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus thoracic muscle plane block (TTPB) with general anesthesia (GA) and 15 mL of 0.25% bupivacaine
Study: 34803399
Drug: Transversus thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus thoracic muscle plane block (TTPB) with GA and 15 mL of 0.25% bupivacaine
Study: 34803399
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (GA) with saline injection
Study: 32740972
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg once per day for 10 days
Study: 32980829
Drug: Chlorhexidine -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine - Chitosan combination
Study: 33440437
Drug: EUS-guided intratumoral
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided intratumoral radioactive phosphorus-32 (32P) implantation followed by six chemotherapy cycles
Study: 32732620
Drug: High vagal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High vagal efficiency treatment group
Study: 32880803
Drug: Low-dose rivaroxaban
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rivaroxaban
Study: 36100927
Drug: HBOT (Hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOT (Hyperbaric Oxygen Treatment)
Study: 32564365
Drug: Lidocaine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (bolus of 1.5 mg.kg−1, continuous infusion of 2 mg.kg−1.h−1 until end of surgery, then 1 mg.kg−1.h−1 for 1 hour in recovery)
Study: 34060209
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide (initial 3 mg dose)
Study: 32940243
Drug: Treatment attributes
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment attributes (effectiveness and out-of-pocket cost)
Study: 32544350
Drug: Treatment (post-surgery)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (post-surgery)
Study: 35881121
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid
Study: 34753425
Drug: TMQLB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMQLB with 0.4 ml/kg 0.5% ropivacaine
Study: 33081606
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 25 µg
Study: 35508923
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g beetroot (272 mg NO3‐)
Study: 35508923
Drug: 200 g
Normalized name: PEG-200 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g beetroot (544 mg NO3‐)
Study: 35508923
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g beetroot (816 mg NO3‐)
Study: 35508923
Drug: 200-ml solution
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-ml solution containing 1000 mg potassium nitrate (KNO3)
Study: 34404091
Drug: Local vibration
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local vibration therapy (VT)
Study: 32493288
Drug: Cisplatin low
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin low cumulative dose (≤150 mg/m2)
Study: 32493288
Drug: Cisplatin intermediate
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin intermediate cumulative dose (151-250 mg/m2)
Study: 32493288
Drug: Cisplatin high
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin high cumulative dose (>250 mg/m2)
Study: 32493288
Drug: Overall population
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall population (all cumulative doses)
Study: 35103059
Drug: Bromhexine hydrochloride
Normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine hydrochloride (8 mg 3 times per day)
Study: 32104959
Drug: Palatal augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal augmentation prostheses (PAP)
Study: 35554758
Drug: Immuno-sympathoinhibitory EA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-sympathoinhibitory EA treatment
Study: 35554758
Drug: Sympathoinhibitory EA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sympathoinhibitory EA treatment
Study: 32595918
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g soy flour (whole soy group)
Study: 32595918
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g low-fat milk powder + 63 mg daidzein (daidzein group)
Study: 33118636
Drug: Edoxaban (low-dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (low-dose: 15 and 30 mg)
Study: 32887548
Drug: Fremanezumab (quarterly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab (quarterly or monthly)